What is William Blair's Estimate for Medtronic Q2 Earnings?

Key Points

• William Blair has revised its Q2 2026 earnings estimate for Medtronic down to $1.32 per share, slightly below the previous forecast of $1.33.
• Medtronic reported Q2 earnings of $1.26 per share, exceeding analysts' expectations, with total revenue of $8.58 billion for the quarter, marking a 7.7% increase year-over-year.
• The company declared a quarterly dividend of $0.71 per share, with an annualized dividend yield of 3.0%, to be paid on October 17th.

Medtronic PLC (NYSE:MDT - Free Report) - Investment analysts at William Blair dropped their Q2 2026 earnings estimates for shares of Medtronic in a report released on Tuesday, August 19th. William Blair analyst B. Vazquez now expects that the medical technology company will earn $1.32 per share for the quarter, down from their prior forecast of $1.33. William Blair has a "Hold" rating on the stock. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic's Q3 2026 earnings at $1.34 EPS, Q4 2026 earnings at $1.71 EPS, FY2026 earnings at $5.63 EPS, Q1 2027 earnings at $1.37 EPS, Q2 2027 earnings at $1.43 EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at $1.80 EPS and FY2027 earnings at $6.08 EPS.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.03. The business had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.56%. Medtronic's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS.

A number of other equities analysts also recently commented on MDT. Morgan Stanley restated an "overweight" rating and issued a $107.00 price objective (up previously from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. Robert W. Baird upped their price objective on shares of Medtronic from $94.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday. Leerink Partnrs upgraded shares of Medtronic to a "strong-buy" rating in a report on Monday, June 16th. Wolfe Research raised shares of Medtronic from an "underperform" rating to a "peer perform" rating in a research report on Monday, June 30th. Finally, Sanford C. Bernstein raised their price target on Medtronic from $97.00 to $98.00 and gave the company an "outperform" rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $100.54.

Medtronic Stock Performance

Shares of MDT stock opened at $93.1320 on Thursday. Medtronic has a fifty-two week low of $79.29 and a fifty-two week high of $96.25. The stock's 50-day moving average is $89.57 and its two-hundred day moving average is $88.02. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.85 and a quick ratio of 1.42. The firm has a market cap of $119.38 billion, a P/E ratio of 25.66, a PEG ratio of 2.33 and a beta of 0.80.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MDT. Burkett Financial Services LLC raised its stake in shares of Medtronic by 185.0% in the 1st quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company's stock valued at $26,000 after buying an additional 185 shares in the last quarter. 1248 Management LLC bought a new stake in Medtronic in the first quarter valued at about $26,000. Wood Tarver Financial Group LLC acquired a new position in Medtronic in the fourth quarter worth about $27,000. Delos Wealth Advisors LLC bought a new position in Medtronic during the second quarter worth about $27,000. Finally, Columbia River Financial Group LLC acquired a new stake in Medtronic during the first quarter valued at approximately $28,000. 82.06% of the stock is owned by institutional investors.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. Medtronic's payout ratio is currently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.